Literature DB >> 11571308

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells.

G Richter1, M Hayden-Ledbetter, M Irgang, J A Ledbetter, J Westermann, I Körner, K Daemen, E A Clark, A Aicher, A Pezzutto.   

Abstract

The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We used soluble ICOSIg and a newly developed murine anti-human ICOS ligand (ICOSL) monoclonal antibody to further characterize the ICOSL during ontogeny of antigen presenting cells. In a previous study, we found that ICOSL is expressed on monocytes, dendritic cells, and B cells. To define when ICOSL is first expressed on myeloid antigen presenting cells, we examined ICOSL expression on CD34(+) cells in bone marrow. We found that CD34(bright) cells regardless of their myeloid commitment were ICOSL(-), whereas ICOSL was first expressed when CD34 expression diminished and the myeloid marker CD33 appeared. However, acute myeloid leukemia cells were ICOSL-negative, whereas among B-cell malignancies only some cases of the most mature tumors such as prolymphocytic leukemia and hairy cell leukemia were positive. Next, we investigated purified CD34(+) hematopoietic progenitor cells that did not constitutively express ICOSL but were induced to express ICOSL within 12 h after granulocyte/macrophage colony-stimulating factor/tumor necrosis factor alpha (TNF-alpha) stimulation. Interestingly, ICOSL was induced prior to CD80/CD86 induction on CD34(+) cells so that ICOSL was expressed in the absence of CD80/CD86. This suggests that ICOSL is an early differentiation marker along the monocytic/dendritic maturation pathway. Induction of ICOSL was dependent on TNF-alpha and was regulated via NF-kappa B as revealed by use of inhibitors specific for I kappa B alpha phosphorylation such as BAY 11-7082 and BAY 11-7085. The antigen presenting capacity of TNF-alpha stimulated CD34(+) cells was strongly inhibited by ICOSIg fusion proteins or by NF-kappa B inhibition. Thus, TNF-alpha-induced ICOSL expression seemed to be functionally important for the costimulatory capacity of CD34(+) hematopoietic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571308     DOI: 10.1074/jbc.M108509200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function.

Authors:  Javaneh Abbasian; Dolores Mahmud; Nadim Mahmud; Sandeep Chunduri; Hiroto Araki; Pavan Reddy; Ronald Hoffman; Mario Arpinati; James L M Ferrara; Damiano Rondelli
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

Review 2.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Competition within the virus-specific CD4 T-cell pool limits the T follicular helper response after influenza infection.

Authors:  Matthew R Olson; Brendon Y Chua; Kim L Good-Jacobson; Peter C Doherty; David C Jackson; Stephen J Turner
Journal:  Immunol Cell Biol       Date:  2016-04-22       Impact factor: 5.126

4.  TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways.

Authors:  Dario Coletti; Ellen Yang; Giovanna Marazzi; David Sassoon
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

5.  ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.

Authors:  Ryoichi Iwata; Joo Hyoung Lee; Mikio Hayashi; Umberto Dianzani; Kohei Ofune; Masato Maruyama; Souichi Oe; Tomoki Ito; Tetsuo Hashiba; Kunikazu Yoshimura; Masahiro Nonaka; Yosuke Nakano; Lyse Norian; Ichiro Nakano; Akio Asai
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

6.  ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells.

Authors:  Saman Khayyamian; Andreas Hutloff; Kerstin Büchner; Michael Gräfe; Volker Henn; Richard A Kroczek; Hans W Mages
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

7.  Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells.

Authors:  Jaya Ahuja; Karan Kampani; Suman Datta; Brian Wigdahl; Katherine E Flaig; Pooja Jain
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

8.  Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.

Authors:  P Sakthivel; J Grunewald; A Eklund; D Bruder; J Wahlström
Journal:  Clin Exp Immunol       Date:  2015-11-24       Impact factor: 4.330

9.  CD34+ circulating cells display signs of immune activation in patients with acute coronary syndrome.

Authors:  Lisa Riesinger; Michael Saemisch; Markus Nickmann; Heiko Methe
Journal:  Heart Vessels       Date:  2018-07-12       Impact factor: 2.037

Review 10.  The emerging role of immune checkpoint based approaches in AML and MDS.

Authors:  Prajwal Boddu; Hagop Kantarjian; Guillermo Garcia-Manero; James Allison; Padmanee Sharma; Naval Daver
Journal:  Leuk Lymphoma       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.